Natixis Advisors LLC Reduces Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Natixis Advisors LLC lowered its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 7.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,042 shares of the company’s stock after selling 864 shares during the period. Natixis Advisors LLC’s holdings in CRISPR Therapeutics were worth $472,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Global Trust Asset Management LLC lifted its stake in shares of CRISPR Therapeutics by 150.0% in the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after acquiring an additional 300 shares during the period. Larson Financial Group LLC increased its holdings in CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after acquiring an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC grew its holdings in shares of CRISPR Therapeutics by 99.7% during the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after buying an additional 307 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of CRISPR Therapeutics during the second quarter worth about $35,000. Finally, Denver PWM LLC purchased a new stake in shares of CRISPR Therapeutics during the second quarter worth about $45,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 30,000 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00. Following the completion of the sale, the chief executive officer now owns 196,540 shares of the company’s stock, valued at $10,931,554.80. This trade represents a 13.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. This represents a 1.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 35,382 shares of company stock valued at $1,917,679 over the last ninety days. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Stock Up 3.1 %

Shares of NASDAQ CRSP opened at $50.84 on Friday. The stock’s fifty day simple moving average is $48.05 and its 200 day simple moving average is $51.69. The stock has a market capitalization of $4.34 billion, a price-to-earnings ratio of -17.96 and a beta of 1.67. CRISPR Therapeutics AG has a 52-week low of $43.42 and a 52-week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. During the same quarter last year, the business posted ($1.41) EPS. As a group, analysts anticipate that CRISPR Therapeutics AG will post -5.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Barclays decreased their target price on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research note on Thursday, November 7th. Chardan Capital lowered their target price on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Royal Bank of Canada restated a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Finally, Needham & Company LLC restated a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $74.94.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.